High Clopidogrel Dose Versus Prasugrel and Ticagrelor in High Reactive Stable Patients
Launched by UNIVERSITY OF ROMA LA SAPIENZA · Mar 2, 2012
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients underwent to percutaneous coronary intervention (PCI)
- • clopidogrel resistance after Platelet reactivity blood test
- Exclusion Criteria:
- • history of bleeding diathesis
- • chronic oral anticoagulation treatment
- • contraindications to antiplatelet therapy
- • PCI or coronary artery bypass grafting (CABG) \< 3 months
- • hemodynamic instability
- • platelet count \< 100,000/μl
- • hematocrit \< 30%
- • creatinine clearance \< 25 ml/min
- • Patients with a history of stroke
- • contraindication for prasugrel administration
- • patients weighing \< 60 kg
- • \> 75 years of age.
About University Of Roma La Sapienza
The University of Roma La Sapienza, one of Italy's premier research institutions, is dedicated to advancing medical science and improving patient outcomes through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university harnesses its extensive expertise in diverse fields, including medicine, biotechnology, and public health, to conduct rigorous and ethically sound research. Committed to fostering educational excellence and promoting groundbreaking discoveries, La Sapienza actively engages in clinical trials that aim to address critical health challenges and contribute to the development of new therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rome, , Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials